2
Roland Decorvet, Chairman & CEO of Nestlé China, to join the organization Mercy Ships as Managing Director of its hospital ship Africa Mercy (PICTURE)
mehr
Storys zum Thema Medicale
MAQUET AND SWISSTOM GIVE NOTICE OF DISTRIBUTION PARTNERSHIP FOR WESTERN EUROPE
Rastatt, Landquart (ots) - MAQUET and Swisstom are pleased to announce their distribution partnership for the monitoring and diagnostic product Swisstom BB2. Acute Lung Injury is still a leading cause of death for intensive care patients. Swisstom BB2 was especially developed to continuously monitor the lung function of ICU patients undergoing mechanical ventilation. ...
mehrHelsinn announces European Medicines Agency acceptance of regulatory submission for netupitant-palonosetron fixed dose combination (NEPA)
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
mehrE.S.PKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria)
European Society for Phenylketonuria calls for minimum standard of care across Europe
Alter, Belgium (ots) - First ever pan-European perspective on optimal care identifies key challenges in this rare genetic disease The first ever pan-European patient/carer perspective on optimal care of the rare genetic disorder phenylketonuria (PKU) has been published in the Orphanet Journal of Rare Diseases. This paper, supported by the European Society for ...
mehrHelsinn Group and Angelini ink an agreement for license rights to phase-III ghrelin receptor agonist Anamorelin in Central & Eastern Europe
Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
mehrTakeda Pharmaceuticals International GmbH
Dexlansoprazole, a new dual-delayed release technology for the treatment of reflux disease, accepted for national approvals within the European Union
Zurich Switzerland (ots) - Takeda Pharmaceuticals International GmbH ("Takeda") announced that the European decentralised procedure (DCP) was positively concluded for dexlansoprazole, a proton pump inhibitor (PPI) with a new dual- delayed release technology for the treatment of reflux disease. The regulatory process ...
mehr
Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agonist Anamorelin in Italy
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
mehrGrünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®
Aachen, Germany / Redwood City (California), USA (ots) - Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self- administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, ...
mehrEuropean Society for Medical Oncology (ESMO)
Defending Medical Oncology to Assure Quality Care for Cancer Patients / ESMO releases position paper on medical oncologist's role
Lugano (ots) - Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says (http://www.presseportal.ch/go2/new_position_statement ). Medical oncologists are specialist cancer physicians ...
mehrEuropean Society for Medical Oncology (ESMO)
Untreated cancer pain a 'scandal of global proportions,' ESMO-led survey shows / New global study reveals a pandemic of intolerable pain affecting billions, caused by pain medicines overregulation
Lugano (ots) - A ground-breaking international survey published today, shows that more than half of the world's population live in countries where regulations aiming to stem drug misuse leave patients without access to opioid medicines for managing cancer pain. The results from the Global Opioid Policy Initiative ...
mehrHelsinn to launch sales organization in the United States
Lugano, Switzerland (ots) - The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi® (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The ...
mehrITM Isotope Technologies Munich SE
Acquisition of exclusive manufacturing and marketing rights for DOTATOC
Garching (ots) - - In-licensing of superior DOTA-Tyr3-octreotide - Pharmaceutical development for treatment of NETs - Excellent pharmacokinetic properties ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development and commercialization of ...
mehr
Better prospects for the future using modern hospital design / The European Trade Fair "Hospital Build & Infrastructure Europe?
Hamburg/Düsseldorf (ots) - The European trade fair "Hospital Build & infrastructure Europe" will be held in the Congress Center Hamburg from 3 to 4 September 2013. Hospital managers, architects, planners and investors, as well as facility managers, will meet here for the third time to exchange experiences. The ...
mehrHelsinn and Advancell sign a partnering agreement for ATH008, a new compound for chemotherapy-induced dermatological injuries
Lugano, Switzerland and Barcelona, Spain (ots) - The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or ...
mehrSoho Flordis International (SFI)
SFI Acquires Ginsana from Pharmaton to Strengthen Global Position in Clinically Proven Natural Medicine
Bioggio, Switzerland (ots) - Pharmaton and Soho Flordis International (SFI), an international provider of clinically proven natural medicines, announced today the acquisition of Ginsana SA, a leader and innovator in natural medicine products. The acquisition from Pharmaton, a company of the Boehringer Ingelheim ...
mehr23rd European Meeting on Hypertension and Cardiovascular Protection
München (ots) - New data from the SEVITENSION study show the fixed-dose combination treatment Sevikar® (olmesartan/amlodipine) to be superior to perindopril in combination with amlodipine in reducing central blood pressure When the traditional arm (brachial) method of measurement is used, blood pressure is usually found to be higher than it is in the large central ...
mehrHelsinn and Zealand announce Helsinn's decision to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
mehrGrünenthal presents a new website for the topical treatment of postherpetic neuralgia (PHN)
Aachen (ots) - Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabbing, or shooting pain, and caused by a previous herpes zoster infection (commonly known as shingles). The new ...
mehr
World Hypertension Day 2013: New Sevikar® data and the Daiichi Sankyo patient support programme highlight importance of effective blood pressure management
Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk of serious cardiovascular events * The Daiichi Sankyo myHypertensionCare patient support programme aims to improve patient engagement and ...
mehrHelsinn and Vifor Pharma sign Licensing and Distribution agreement for Netupitant-Palonosetron fixed dose combination
Lugano/Glattbrugg, Switzerland (ots) - Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of ...
mehrThe International Osteoporosis Foundation (IOF)
New data reveal increasing burden of osteoporosis in Europe
Rome, Italy (ots) - Every year 43,000 people die following osteoporotic fractures; reports show that European healthcare systems are not treating people at risk; burden and costs will rise dramatically by 2025. Two landmark multi-stakeholder reports launched today - Osteoporosis in the European Union and the Scorecard for Osteoporosis in Europe - describe and compare the epidemiology, burden, and management of ...
mehrEndomagnetics Appoints Strategic Distributor
Norderstedt (ots) - Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has announced it has signed a distribution agreement with Sysmex Europe GmbH, a subsidiary of global healthcare company Sysmex Corporation. Sysmex has the exclusive right to provide sales and support for Endomagnetics' SentiMag® system across the EMEA region. This is Endomagnetics' first ...
mehrPrionics: Favourable assessment of BOVIGAM® tuberculosis test in Europe
Schlieren-Zurich (ots) - The European Food Safety Authority (EFSA) has reviewed field performance data of the BOVIGAM® Interferon-y (IFN-y) test and recommends IFN-y tests for inclusion in the official list of stand-alone tests for bovine tuberculosis (TB). BOVIGAM® is currently widely used as a supplementary test to complement skin testing. Prionics trusts that the ...
mehrPalonosetron infusion bag launched in Japan
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
mehr
Prague: Battleground in the fight against retinal diseases / 12th International AMD and Retina Congress in Prague, 2-3 Nov 2012
Lugano, Switzerland (ots) - ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which covered the whole spectrum of retinopathy, this year's meeting in the Czech Republic takes a significant step ...
mehrSequana Medical receives CE-mark approval for the use of its alfapump® system in cancer patients with malignant ascites
Zurich, Switzerland (ots) - Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites ...
mehrPreclinical Data Support the Potential of AmVacs RSV Vaccine / Innovative approach to the prevention of severe respiratory infections
Zug (ots) - AmVac AG has announced that it has made decisive progress in the development of their new RSV vaccine. The vaccine candidate is based on AmVac's innovative Sendai virus vector platform and developed for the prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus). RSV ...
mehrBioforce AG: Largest Echinacea trial proves prevention of colds and flu
Roggwil, Switzerland (ots) - Colds and flu are the most frequent illnesses experienced by the Western world. They lead to tremendous costs to public health and the economy, being the leading cause of absences from work and school. This is especially the case during the autumn and winter months when almost everyone suffers colds or flu a few times. Immune resistance ...
mehrITG Isotope Technologies Garching GmbH
ITG and NTP Cooperation - Milestone in Global Security of Supply for Radioisotope Industry
Garching (ots) - ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative radioisotopes - expands its nuclear reactor and technology network in line with its strategy to guarantee global security of supply. In May 2012, ITG - a fully-owned subsidiary of ITM Isotopen Technologien München AG (ITM) based in Germany - and NTP Radioisotopes SOC Ltd (NTP) - a ...
mehrPevion mandated patient survey confirms disease burden of recurrent vulvovaginal candidiasis (RVVC) and indicates public health problem
Bern, Switzerland (ots) - - - Quality of Life (QoL) is strongly diminished in RVVC patients - Current available treatment fails in two thirds of patients - High medical need demands novel effective treatment options Pevion Biotech AG today announced results from a large, international survey on the Quality of Life ...
mehr
Vorherige38394041424344454647Nächste